Tyra Biosciences (TYRA) Stock Price, News & Analysis

Company Overview

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells. Lead candidates are designed to inhibit key enzymes and signaling pathways implicated in tumor growth and survival. Tyra Biosciences collaborates with academic research centers and employs translational biomarker strategies to streamline clinical development and patient selection.

Headquartered in South San Francisco, California, Tyra Biosciences operates with a global outlook, engaging with regulatory authorities and clinical investigators across North America and Europe. The company is led by a team of executives and scientists with extensive experience in oncology drug development, aiming to bring novel targeted therapies from discovery through clinical proof-of-concept.

Key Stats

• Today's Range: $25.46 to $30.59
• 50-Day Range: $25.42 to $33.41
• 52-Week Range: $9.96 to $40.65
• Volume: 2.74 million shs
• Average Volume: 552,172 shs
• Market Capitalization: $1.53 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.90
• Consensus Rating: Moderate Buy

Tyra Biosciences Stock Analysis - MarketRank™

Tyra Biosciences scored higher than 54% of companies evaluated by MarketBeat, and ranked 425th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tyra Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 1 strong buy rating, 12 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Tyra Biosciences has a consensus price target of $46.90, representing about 82.4% upside from its current price of $25.71.

Amount of Analyst Coverage

Tyra Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tyra Biosciences are expected to decrease in the coming year, from ($2.68) to ($2.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tyra Biosciences is -10.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tyra Biosciences is -10.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tyra Biosciences has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.08% of the float of Tyra Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Tyra Biosciences has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Tyra Biosciences has recently decreased by 16.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tyra Biosciences does not currently pay a dividend.

Dividend Growth

Tyra Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.25

News Sentiment

Tyra Biosciences has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Tyra Biosciences this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tyra Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.50% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 8/06/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TYRA
• CIK: 1863127
• Web: www.tyra.bio
• Phone: 619-728-4760
• Fax: N/A
• Employees: 20
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Tyra Biosciences: $46.90
• High Price Target: $56.00
• Low Price Target: $35.00
• Potential Upside/Downside: +82.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.87
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$119.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -48.07%
• Return on Assets: -44.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.49
• Quick Ratio: 20.49

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.86 per share
• Price / Book: 5.29

Miscellaneous

• Outstanding Shares: 59,470,000
• Free Float: 52,036,000
• Market Cap: $1.53 billion
• Optionable: Optionable
• Beta: 0.77